MedTrace Logo

Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro

NCT02104440 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-03-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of the sequential infusion of allogeneic mesenchymal stem cells (MSC), expanded "in vitro" with platelet lysate without addition of animal products in the treatment of patients undergoing allo-HSCT who developed one or more cytopenias.

Conditions

  • Cytopenia

Interventions

BIOLOGICAL

Sequential infusion of allogeneic mesenchymal stem cells expanded "in vitro"

Sponsors & Collaborators

  • University of Navarrra Hospital (Clinica Universitaria)

    collaborator OTHER

  • Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán

    collaborator OTHER

  • Hospitales Universitarios Virgen del Rocío

    collaborator OTHER

  • Spanish National Health System

    collaborator OTHER

  • Red de Terapia Celular

    lead INDUSTRY

Principal Investigators

  • Fermín Sánchez-Guijo Martín, Ph.D · University Clinical Hospital of Salamanca

  • José Rifón Roca, Ph.D · University of Navarrra Hospital (Clinica Universitaria)

  • José A Pérez Simón, Ph.D · Hospital Virgen del Rocío

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104440 on ClinicalTrials.gov